CA2950960A1 - Polynucleotide constructs having bioreversible and non-bioreversible groups - Google Patents

Polynucleotide constructs having bioreversible and non-bioreversible groups Download PDF

Info

Publication number
CA2950960A1
CA2950960A1 CA2950960A CA2950960A CA2950960A1 CA 2950960 A1 CA2950960 A1 CA 2950960A1 CA 2950960 A CA2950960 A CA 2950960A CA 2950960 A CA2950960 A CA 2950960A CA 2950960 A1 CA2950960 A1 CA 2950960A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
alkyl
polynucleotide construct
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2950960A
Other languages
English (en)
French (fr)
Inventor
Curt W. Bradshaw
Sukumar Sakamuri
Laxman Eltepu
Son Lam
Dingguo Liu
Bryan Meade
Giuseppe Dello Iacono
Joseph Stock
Bin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLSTICE BIOLOGICS Ltd
Original Assignee
SOLSTICE BIOLOGICS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLSTICE BIOLOGICS Ltd filed Critical SOLSTICE BIOLOGICS Ltd
Publication of CA2950960A1 publication Critical patent/CA2950960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2950960A 2014-06-06 2015-06-08 Polynucleotide constructs having bioreversible and non-bioreversible groups Abandoned CA2950960A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009123P 2014-06-06 2014-06-06
US62/009,123 2014-06-06
PCT/US2015/034749 WO2015188197A2 (en) 2014-06-06 2015-06-08 Polynucleotide constructs having bioreversible and non-bioreversible groups

Publications (1)

Publication Number Publication Date
CA2950960A1 true CA2950960A1 (en) 2015-12-10

Family

ID=54767614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2950960A Abandoned CA2950960A1 (en) 2014-06-06 2015-06-08 Polynucleotide constructs having bioreversible and non-bioreversible groups

Country Status (7)

Country Link
US (2) US20170114341A1 (enExample)
EP (1) EP3152308A4 (enExample)
JP (1) JP2017522046A (enExample)
CN (1) CN107109405A (enExample)
AU (1) AU2015269053A1 (enExample)
CA (1) CA2950960A1 (enExample)
WO (1) WO2015188197A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA3021580A1 (en) 2015-06-25 2016-12-29 Barry L. Merriman Biomolecular sensors and methods
WO2017100461A1 (en) * 2015-12-08 2017-06-15 Solstice Biologics, Ltd. Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CN113985017A (zh) 2016-01-14 2022-01-28 罗斯韦尔生物技术股份有限公司 分子传感器及相关方法
EP3408219B1 (en) 2016-01-28 2022-08-17 Roswell Biotechnologies, Inc Massively parallel dna sequencing apparatus
JP7280590B2 (ja) 2016-01-28 2023-05-24 ロズウェル バイオテクノロジーズ，インコーポレイテッド 大スケールの分子電子工学センサアレイを使用する被分析物を測定するための方法および装置
KR20240170584A (ko) 2016-02-09 2024-12-03 로스웰 엠이 아이엔씨. 전자 비표지 dna 및 게놈 시퀀싱
US10597767B2 (en) 2016-02-22 2020-03-24 Roswell Biotechnologies, Inc. Nanoparticle fabrication
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
US9829456B1 (en) 2016-07-26 2017-11-28 Roswell Biotechnologies, Inc. Method of making a multi-electrode structure usable in molecular sensing devices
CN109844513A (zh) * 2016-08-01 2019-06-04 罗斯韦尔生物技术股份有限公司 用于分子电子传感器的经修饰的核苷酸三磷酸
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
CN114891053A (zh) 2016-08-23 2022-08-12 迪克纳制药公司 包含可逆修饰的寡核苷酸的组合物及其用途
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
UY37565A (es) 2017-01-10 2018-07-31 Arrowhead Pharmaceuticals Inc Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
KR102622275B1 (ko) 2017-01-10 2024-01-05 로스웰 바이오테크놀로지스 인코포레이티드 Dna 데이터 저장을 위한 방법들 및 시스템들
CA3052140A1 (en) 2017-01-19 2018-07-26 Roswell Biotechnologies, Inc. Solid state sequencing devices comprising two dimensional layer materials
KR102808275B1 (ko) 2017-04-14 2025-05-20 탈락 테라퓨틱스, 인크. 면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
EP3615685B1 (en) 2017-04-25 2025-02-19 Roswell Biotechnologies, Inc Enzymatic circuits for molecular sensors
US10508296B2 (en) 2017-04-25 2019-12-17 Roswell Biotechnologies, Inc. Enzymatic circuits for molecular sensors
EP4023764A3 (en) 2017-05-09 2022-09-21 Roswell Biotechnologies, Inc. Binding probe circuits for molecular sensors
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
JP7282379B2 (ja) * 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
CN111373049A (zh) 2017-08-30 2020-07-03 罗斯威尔生命技术公司 用于dna数据存储的进行性酶分子电子传感器
CN111373051A (zh) 2017-10-10 2020-07-03 罗斯威尔生命技术公司 用于无扩增dna数据存储的方法、装置和系统
HRP20230023T1 (hr) 2017-10-20 2023-03-17 Dicerna Pharmaceuticals, Inc. Postupci liječenja infekcije hepatitisom b
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110997919B (zh) 2017-12-01 2024-04-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
CN118236391A (zh) 2017-12-01 2024-06-25 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN110959011B (zh) * 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2019143621A1 (en) 2018-01-16 2019-07-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting aldh2 expression
BR112020016524A2 (pt) 2018-02-14 2021-09-28 Deep Genomics Incorporated Terapia com oligonucleotídeos para a doença de wilson
EP3790970A1 (en) 2018-05-07 2021-03-17 Alnylam Pharmaceuticals Inc. Extrahepatic delivery
JP7616987B2 (ja) 2018-07-13 2025-01-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
BR112021007294A2 (pt) * 2018-10-17 2021-07-27 Tallac Therapeutics, Inc. imunomodulação de conjugados de polinucleotídeos e métodos de uso
US11249941B2 (en) * 2018-12-21 2022-02-15 Palo Alto Research Center Incorporated Exabyte-scale data storage using sequence-controlled polymers
CN112423795A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN112423794A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3908661A1 (en) 2019-02-12 2021-11-17 Dicerna Pharmaceuticals, Inc. Methods and compositions for inhibiting expression of cyp27a1
WO2020206350A1 (en) 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
JP7663951B2 (ja) 2019-05-22 2025-04-17 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN113811613B (zh) 2019-05-22 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
WO2020238766A1 (zh) 2019-05-24 2020-12-03 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN118217305A (zh) * 2019-05-24 2024-06-21 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP3980540A4 (en) 2019-06-06 2023-11-01 Arrowhead Pharmaceuticals, Inc. METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
CN112390835A (zh) * 2019-08-14 2021-02-23 苏州瑞博生物技术股份有限公司 肝靶向化合物及缀合物
EP4023659A4 (en) * 2019-08-29 2024-02-28 Suzhou Ribo Life Science Co., Ltd. COMPOUND AND DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF
AU2020358016A1 (en) 2019-10-02 2022-04-21 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering RNA with minimal fluorine content
AU2020399633A1 (en) 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
AU2020410993A1 (en) 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CN114828852A (zh) 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
US20230287425A1 (en) 2020-03-18 2023-09-14 Dicerna Pharmacuticals Inc. Compositions and methods for inhibiting angptl3 expression
CA3187220A1 (en) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
AU2021322891A1 (en) 2020-08-05 2023-03-09 Dicerna Pharmaceuticals, Inc. Oligonucleotide treatment of hepatitis B patients
TW202535432A (zh) 2020-08-05 2025-09-16 美商戴瑟納製藥股份有限公司 抑制lpa表現之組合物及方法
MX2023004109A (es) 2020-10-08 2023-06-28 Dicerna Pharmaceuticals Inc Administracion selectiva de oligonucleótidos a células gliales.
US20230390403A1 (en) * 2020-10-14 2023-12-07 North Carolina State University Compositions and methods for drug delivery
EP4285937A4 (en) * 2021-01-28 2025-11-19 Nanjing Chempion Biotechnology Co Ltd CONJUGATED AND ITS USE
WO2022221430A1 (en) 2021-04-14 2022-10-20 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating pnpla3 expression
IL312635A (en) 2021-11-11 2024-07-01 Hoffmann La Roche Pharmaceutical combinations for treatment of hbv
EP4441218A2 (en) 2021-12-01 2024-10-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating apoc3 expression
EP4450512A4 (en) * 2021-12-17 2025-12-24 Liid Pharmaceuticals Inc OLIGONUCLEOTIDE PRODUCTION PROCESS
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
CA3245064A1 (en) 2022-04-15 2023-10-19 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF STRUCTURAL AND CYTOSKELETON-ASSOCIATED PROTEINS
WO2024093947A1 (zh) * 2022-10-31 2024-05-10 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
WO2024097310A2 (en) * 2022-11-01 2024-05-10 Impilo Therapeutics, Inc. Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
CN115925586A (zh) * 2022-11-01 2023-04-07 青岛蓝谷多肽生物医药科技有限公司 一种靶向psma的母体及其衍生物的制备方法
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN116925160B (zh) * 2023-09-15 2023-12-08 天津全和诚科技有限责任公司 一种GalNAc含糖环中间体及其制备方法
WO2025235911A2 (en) * 2024-05-09 2025-11-13 Wave Life Sciences Ltd. Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2340309A2 (en) * 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
CN102459302A (zh) * 2009-06-01 2012-05-16 加利福尼亚大学董事会 核酸递送组合物及其使用方法
EP2885313A4 (en) * 2012-08-20 2016-03-09 Univ California POLYNUCLEOTIDES WITH BIOREVERSIBLE GROUPS
JP2016537027A (ja) * 2013-11-06 2016-12-01 ソルスティス バイオロジクス，リミティッド ジスルフィド基を有するポリヌクレオチド構築物

Also Published As

Publication number Publication date
AU2015269053A1 (en) 2016-12-22
WO2015188197A2 (en) 2015-12-10
CN107109405A (zh) 2017-08-29
JP2017522046A (ja) 2017-08-10
US20200392498A1 (en) 2020-12-17
US20170114341A1 (en) 2017-04-27
EP3152308A2 (en) 2017-04-12
WO2015188197A3 (en) 2016-02-25
EP3152308A4 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
US20160257961A1 (en) Polynucleotide constructs having disulfide groups
AU2013306006B2 (en) Polynucleotides having bioreversible groups
US20240247025A1 (en) Polynucleotide constructs
CA3089276A1 (en) Trialkyne linking agents and methods of use
AU2022221483A1 (en) Oligonucleotide compositions and methods thereof
US20190194655A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CA3120580A1 (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
AU2022349576A1 (en) Multivalent ligand clusters with diamine scaffold for targeted delivery of therapeutic agents
JP2025536115A (ja) 膜貫通送達系およびその使用
KR20260056195A (ko) 올리고뉴클레오타이드의 세포내 표적화

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123